Seamus Mulligan Net Worth

The estimated Net Worth of Seamus Mulligan is at least $403 millió dollars as of 8 June 2023. Mr. Mulligan owns over 4,500 units of Jazz Pharmaceuticals plc stock worth over $122,928,509 and over the last 13 years he sold JAZZ stock worth over $279,260,884. In addition, he makes $542,573 as Independent Director at Jazz Pharmaceuticals plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Mulligan JAZZ stock SEC Form 4 insiders trading

Seamus has made over 18 trades of the Jazz Pharmaceuticals plc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 4,500 units of JAZZ stock worth $367,920 on 8 June 2023.

The largest trade he's ever made was selling 2,000,000 units of Jazz Pharmaceuticals plc stock on 9 March 2012 worth over $99,120,000. On average, Seamus trades about 106,783 units every 125 days since 2012. As of 8 June 2023 he still owns at least 1,169,300 units of Jazz Pharmaceuticals plc stock.

You can see the complete history of Mr. Mulligan stock trades at the bottom of the page.

Seamus Mulligan biography

Seamus C. Mulligan serves as Independent Director of the Company. Mr. Seamus Mulligan has served as a member of our board of directors since the closing of the Azur Merger in January 2012 and was a founder and principal investor of Azur Pharma. From 2014 until 2018, Mr. Mulligan served as Chairman and Chief Executive Officer of Adapt Pharma Ltd., a specialty pharmaceutical company, which was acquired in October 2018 by Emergent BioSolutions Inc., a multinational specialty biopharmaceutical company, where Mr. Mulligan served on the board of directors from March 2019 until May 2020. From 2006 until April 2017, Mr. Mulligan served as Executive Chairman of Circ Pharma Limited and its subsidiaries, a pharmaceutical development stage group. Mr. Mulligan served as our Chief Business Officer, International Business Development from the closing of the Azur Merger until February 2013. Mr. Mulligan served as Azur Pharma’s Chairman and Chief Executive Officer and as a member of its board of directors from 2005 until the closing of the Azur Merger. From 1984 until 2004, he held various positions with Elan Corporation, plc, a pharmaceutical company, most recently as Executive Vice President, Business and Corporate Development, and prior to that position, held the roles of President of Elan Pharmaceutical Technologies, the drug delivery division of Elan Corporation, plc, Executive Vice President, Pharmaceutical Operations, Vice President, U.S. Operations and Vice President, Product Development. He served as a member of the board of directors of the U.S. National Pharmaceutical Council until 2004. Mr. Mulligan received a B.Sc. (Pharm) and M.Sc. from Trinity College Dublin.

What is the salary of Seamus Mulligan?

As the Independent Director of Jazz Pharmaceuticals plc, the total compensation of Seamus Mulligan at Jazz Pharmaceuticals plc is $542,573. There are 15 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of $14,713,600.

How old is Seamus Mulligan?

Seamus Mulligan is 59, he's been the Independent Director of Jazz Pharmaceuticals plc since 2012. There are 7 older and 21 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.

What's Seamus Mulligan's mailing address?

Seamus's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .

Insiders trading at Jazz Pharmaceuticals plc

Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright és Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.

What does Jazz Pharmaceuticals plc do?

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni

Complete history of Mr. Mulligan stock trades at Jazz Pharmaceuticals plc és Emergent Biosolutions Inc

Jazz Pharmaceuticals plc executives and stock owners

Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include:

• Bruce Cozadd,
  Chairman of the Board, Chief Executive Officer
• Daniel Swisher,
  President, Chief Operating Officer
• Robert Iannone,
  Executive Vice President, Research and Development
• Neena Patil,
  Senior Vice President, General Counsel
• Bruce C. Cozadd,
  Co-Founder, Chairman & CEO
• Daniel N. Swisher Jr.,
  Pres
• Anne O'Riordan,
  Independent Director
• Dr. Robert Iannone M.D.,
  Exec. VP of R&D and Chief Medical Officer
• Renee D. Gala,
  Exec. VP & CFO
• Kim Sablich,
  Exec. VP & GM of North America
• Rick Winningham,
  Independent Director
• Heather McSharry,
  Independent Director
• Peter Gray,
  Independent Director
• Norbert Riedel,
  Independent Director
• Patrick Enright,
  Independent Director
• Catherine Sohn,
  Independent Director
• Elmar Schnee,
  Independent Director
• Seamus Mulligan,
  Independent Director
• Kenneth O'Keefe,
  Independent Director
• Paul Berns,
  Independent Director
• Diane Schrick,
  Senior Director, Investor Relations
• Patricia Carr,
  Vice President, Finance and Principal Accounting Officer
• Samantha Pearce,
  Senior Vice President, Europe and Rest of World
• Finbar Larkin,
  Senior Vice President - Technical Operations
• Kimberly Sablich,
  Executive Vice President, General Manager - North America
• Renee Gala,
  Chief Financial Officer, Executive Vice President
• Neena M. Patil J.D.,
  Chief Legal Officer and Sr. VP of Legal & Corp. Affairs
• Andrea N. Flynn,
  VP & Head of Investor Relations
• Dr. Finbar Larkin Ph.D.,
  Sr. VP of Technical Operations
• Patricia Carr,
  VP of Fin. & Principal Accounting Officer
• Christopher John Tovey,
  Exec. VP, COO and MD of Europe & International
• Paul Treacy,
  SVP, Technical Operations
• Suzanne Sawochka Hooper,
  EVP and General Counsel
• Karen L. Smith,
  Global Head of R&D and CMO
• Karen J Wilson,
  VP of Finance & PAO
• Russell J. Cox,
  SVP, Sales and Marketing
• Iain Mc Gill,
  Head of EUSA Int'l & SVP
• Matthew P. Young,
  SVP & CFO
• Michael Patrick Miller,
  EVP, US Commercial
• Jennifer E. Cook,
  Director
• Mark Douglas Smith,
  Director
• Jp Llckkr Jp Iii Llckkr Iii...,
  
• Bryan C Cressey,
  Director
• Alan Sebulsky,
  Director
• Kathryn E Falberg,
  SVP and CFO
• Paul Egolkin Perryhuth Joha...,
  
• Michael W Michelson,
  Director
• Samuel D Colella,
  Director
• Financial Holdings Iii, Llc...,
  
• Group Holdings L.P.Kkr Grou...,
  
• Matthew K Fust,
  Senior Vice President & CFO
• Jeffrey K Tobias,
  EVP, Research & Dev and CMO
• Fintan Keegan,
  EVP, Technical Operations
• Cressey Equity Partners Inc...,
  
• Mark G. Eller,
  SVP, Research & Clinical Dev.
• James C Momtazee,
  Director
• Jp Iii Llckkr Partners Iii,...,
  
• Fund Holdings L.P.Kkr Jp Ll...,
  
• Michael A. Des Jardin,
  SVP, Product Development
• Nathaniel M Zilkha,
  Director
• Joan Colligan,
  Principal Accounting Officer
• Janne Lt Wissel,
  Senior VP of Development
• James B Tananbaum,
  Director
• Samuel R Saks,
  Chief Executive Officer
• Robert M Myers,
  President
• E Alexander Albert,
  Director
• Jp Llckkr Jp Iii Llckkr Iii...,
  
• Paul Ehuth Johannes Pfisher...,
  
• Michael W Janetschek Willia...,
  
• Carol A Gamble,
  SVP, GC and Corporate Secty
• Management Llcmignone Rober...,
  
• Henry Rroberts George Rgree...,
  
• Michael Wkkr Financial Hold...,
  
• Paul Ehuth Johannes Pfisher...,
  
• Patel Jaimin,
  Director
• Michael Wkkr Financial Hold...,
  
• Kim Sablich,
  EVP, GM of U.S.
• Mary Elizabeth Henderson,
  SVP, Technical Operations
• Christopher J. Tovey,
  EVP, COO & Managing Director E
• Laura Hamill,
  Director
• Patrick Kennedy,
  Director
• Philip L Johnson,
  EVP & Chief Financial Officer